2013

ISPOR Europe 2013, 2-6 November, Dublin, Ireland

  • >view Posters, presentations, workshops

Issue Panels

  • How can health economic modellers win the trust of decision makers?

Workshops

  • Managing uncertainty: the new way forward for market access

Podium presentations

  • Bayesian calibration method to estimate transition probabilities for a Markov model based on a continuous outcome measure: application in Parkinson’s disease

  • Incremental Cost per Quality-Adjusted Life Year Gained? The Need for Alternative Methods to Evaluate Medical Interventions for Ultra-Rare Disorders

  • Impact of exclusive hospital distribution of biosimilar on drug healthcare budget

  • Overview of coverage with evidence development in Sweden

Posters

  • >view Re-establishing the full value of pediatric combination vaccines

  • >view Identification of the treatment pathway of metastatic castrate-resistant prostate cancer in Scotland: a chart review

  • >view The new Italian healthcare reform: introducing new measures to speed up market access

  • >view Coverage with Evidence Development in Sweden – Formality or effective way to reduce uncertainty?

  • >view Dispensation conditions of anti-TNFs in inflammatory bowel disease

  • The cost-effectiveness of intravitreal aflibercept (ivt-afl) in treating neovascular age-related macular degeneration in an Italian setting

  • >view Patient-level Markov model to assess economic impact of new antipsychotics introduction in schizophrenia

  • >view How should an antidepressant with reduced risk of sexual dysfunction be positioned in treatment strategies for patients with major depressive disorder?

  • >view Comparative efficacy and metabolic profile of lurasidone for the management of acute schizophrenia: a systematic literature review and mixed treatment comparison with first and second generation antipsychotics

  • >view Divergence of HTA decisions across countries: case analysis of ivabradine

  • Budget impact analysis of rivaroxaban in the prevention of stroke in non-valvular atrial fibrillation patients in Italy

  • Cost-effectiveness of rivaroxaban in the prevention of stroke in non-valvular atrial fibrillation patients in Italy

  • >view Modelling the natural history of schizophrenia: comparison of naïve vs. advanced statistical methods

  • >view Validation of Disease States in Schizophrenia: Comparison of Cluster Analysis between US and European Populations 

  • >view Description of treatment pathways in chronic diseases using large general practitioner longitudinal data: the example of pharmaco-therapy in Parkinson’s disease in the UK.

  • >view Cost-effectiveness of mirabegron compared with tolterodine er 4mg for the treatment of patients with overactive bladder in the UK: results from a trial-based model

  • >view Cost-effectiveness of mirabegron compared with antimuscarinics for the treatment of patients with overactive bladder in the UK

  • >view Elicitation of health-related quality of life concepts associated with overactive bladder

  • >view Measuring treatment effects on rare events using meta-analysis: an assessment of existing methods

  • >view Drug compliance and persistence in patients with Parkinson’s disease treated in the UK primary care: a CPRD-based study
  • >view Cost-effectiveness of rivaroxaban in the prevention of stroke in non-valvular atrial fibrillation patients in Italy
  • >view Budget impact analysis of rivaroxaban in the prevention of stroke in non-valvular atrial fibrillation patients in Italy
  • >view The cost-effectiveness of intravitreal aflibercept (ivt-afl) in treating neovascular age-related macular degeneration in an Italian setting

WPA, 27-30 October, Vienna, Austria

Posters

  • Reasons for aripiprazole discontinuation: a retrospective review

ECNP, 5-9 October, Barcelona, Spain

Posters

  • Reasons for aripiprazole discontinuation: a retrospective review

World Congress of Neurology, 21-26 September, Vienna, Austria

Posters

  • Initiation of pharmacological treatment in Parkinson’s disease in the UK: a clinical practice research datalink retrospective study

ISPOR 4th Annual Latin America Conference

Symposium

  • >view Educational Symposium: The role of Multi-Criteria Decision Analysis (MCDA) in Health Technology Assessment (HTA) and reimbursement decision making in Latin America

European Stroke Conference, 28-31 May, London, UK

Posters

  • Hospital Resource utilisation for the management of acute stroke patients in a French stroke unit
  • Management of acute ischaemic stroke over a 12-month period in France, Germany and West Scotland: implications for the introduction of new treatments

ISPOR International Meeting 2013, 18-22 May New Orleans, LA, USA

Posters

  • >view EU pharmaceutical expenditure forecast
  • >view Retrospective study of persistence and healthcare costs in the US opioid-dependent Medicaid population  treated with buprenorphine/naloxone film and tablet formulations
  • >view Analysis of the impact of treatment persistence on health care charges among opioid-dependent patients treated with buprenorphine/naloxone using a US insurance database
  • >view A retrospective study on the burden of cytomegalovirus disease in immunosuppressed persons following transplantation between 2007 and 2011 in France
  • >view Estimation and comparison of utilities generated from a generic (EQ-5D) and disease-specific (OAB-5D) instrument in an overactive bladder population
  • >view Comparative efficacy and safety of treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison
  • >view Innovative methodology for pharmaceutical expenditure forecast
  • >view Pharmaceutical expenditure forecast model to support health policy decision making
  • >view A regression analysis of the impact of patient access schemes

American Psychiatric Association Congress, 18-22 May, San Francisco, CA, USA

Posters

  • Perceptions and Evaluation of Cognitive Functioning Among Psychiatrists From Different Countries in Major Depressive Disorder
  • A systematic literature review of validated cognitive assessment measures for use in schizophrenia, major depressive disorder and/ or bipolar disorder
  • Routine clinical assessment of cognitive functioning in schizophrenia, major depressive disorder, and bipolar disorder

 

 

 

Archives